Concentrix Co. (NASDAQ:CNXC – Get Free Report) shares gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $45.68, but opened at $51.49. Concentrix shares last traded at $59.86, with a volume of 747,478 shares changing hands.
The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.58 by $0.21. Concentrix had a return on equity of 16.67% and a net margin of 2.61%. The business had revenue of $2.37 billion during the quarter, compared to analysts’ expectations of $2.37 billion. During the same period in the prior year, the firm posted $2.57 EPS. The business’s quarterly revenue was down 1.3% compared to the same quarter last year.
Concentrix Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 6th. Shareholders of record on Friday, April 25th will be paid a $0.3328 dividend. The ex-dividend date is Friday, April 25th. This represents a $1.33 annualized dividend and a yield of 2.05%. Concentrix’s dividend payout ratio is currently 35.85%.
Analyst Ratings Changes
Read Our Latest Report on Concentrix
Insider Activity at Concentrix
In related news, Director Kathryn Hayley purchased 500 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were purchased at an average price of $50.22 per share, with a total value of $25,110.00. Following the completion of the acquisition, the director now directly owns 3,034 shares in the company, valued at $152,367.48. This represents a 19.73 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.20% of the stock is owned by insiders.
Institutional Trading of Concentrix
A number of hedge funds have recently added to or reduced their stakes in the stock. CSS LLC IL purchased a new stake in shares of Concentrix during the fourth quarter worth approximately $355,000. PharVision Advisers LLC acquired a new position in Concentrix in the 4th quarter valued at $465,000. Paradigm Capital Management Inc. NY raised its position in Concentrix by 2.7% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 750,142 shares of the company’s stock worth $32,459,000 after buying an additional 19,418 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Concentrix by 15.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 124,769 shares of the company’s stock worth $5,399,000 after acquiring an additional 17,019 shares during the period. Finally, Voloridge Investment Management LLC purchased a new stake in shares of Concentrix in the fourth quarter valued at about $1,202,000. 90.34% of the stock is owned by institutional investors and hedge funds.
Concentrix Trading Up 42.4 %
The firm has a market cap of $4.18 billion, a PE ratio of 17.53, a P/E/G ratio of 0.63 and a beta of 0.69. The company’s fifty day moving average price is $47.90 and its two-hundred day moving average price is $47.85. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 1.17.
About Concentrix
Concentrix Corporation engages in the provision of technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services, across various channels of communication, such as voice, chat, email, social media, asynchronous messaging, and custom applications.
See Also
- Five stocks we like better than Concentrix
- What is the Dogs of the Dow Strategy? Overview and Examples
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- About the Markup Calculator
- Top 3 Beverage Stocks Pouring Out Profits
- What Are Treasury Bonds?
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Concentrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concentrix and related companies with MarketBeat.com's FREE daily email newsletter.